MET and breast carcinoma: Hepatocyte growth factor (HGF) is the native peptide ligand of the MET receptor and aberrant HGF/MET activation drives oncogenic pathways involved in the development and progression of several human cancers, including renal, gastrointestinal, lung, and breast carcinomas, as well as glioblastoma multiforme (GBM) (26, 27).